Single Dose CLR 131 Demonstrates Clinical Benefit in B-Cell Malignancies in Phase II Study

Initial data from the phase II CLOVER-1 trial demonstrated an acceptable safety profile for CLR 131 in patients with relapsed/refractory B-cell malignancies, including multiple myeloma, Cellectar Biosciences, Inc., announced in a press release.

Read the full article here

Related Articles